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Mitochondrial DNA mutations and 
respiratory chain dysfunction in 
idiopathic and connective tissue 
disease-related lung fibrosis
Veronika K. Jaeger1, Dirk Lebrecht2,3, Andrew G. Nicholson4,5, Athol Wells5,6, Harshil Bhayani7, 
Amiq Gazdhar8, Michael tamm9, Nils Venhoff2, thomas Geiser8 & Ulrich A. Walker1
Reactive oxygen species (Ros) are implicated in the aetiology of interstitial lung disease (ILD). We 
investigated the role of large-scale somatically acquired mutations in mitochondrial DNA (mtDNA) and 
consecutive respiratory chain dysfunction as a trigger of ROS-formation and lung fibrosis. Mitochondria 
were analysed in lung biopsies from 30 patients with idiopathic or connective tissue disease (CTD)-
related ILD and 13 controls. In 17 patients we had paired biopsies from upper and lower lobes. Control 
samples were taken from lung cancer resections without interstitial fibrosis. Malondialdehyde, a 
marker of ROS-formation, was elevated in ILD-biopsies (p = 0.044). The activity of the mitochondrial 
respiratory chain (cytochrome c-oxidase/succinate dehydrogenase [COX/SDH]-ratio) was depressed 
in ILD (median = 0.10,) compared with controls (0.12, p < 0.001), as was the expression of mtDNA-
encoded COX-subunit-2 protein normalized for the nucleus-encoded COX-subunit-4 (COX2/COX4-ratio; 
ILD-median = 0.6; controls = 2.2; p < 0.001). Wild-type mtDNA copies were slightly elevated in ILD 
(p = 0.088). The common mtDNA deletion was only present at low levels in controls (median = 0%) and 
at high levels in ILD (median = 17%; p < 0.001). In ILD-lungs with paired biopsies, lower lobes contained 
more malondialdehyde and mtDNA deletions than upper lobes and had lower COX2/COX4-ratios 
and COX/SDH-ratios (all p < 0.001). Acquired mtDNA-mutations and consecutive respiratory chain 
dysfunction may both trigger and perpetuate ROS-formation in ILD.
Interstitial lung disease (ILD) can be idiopathic, or occur in conjunction with systemic sclerosis (SSc) and other 
connective tissue diseases (CTD). A current hypothesis is that ILD results from a sequential ‘multi-hit’ injury 
to lung epithelial cells and that incomplete repair fosters the release of transforming growth factor (TGF) β and 
other profibrotic mediators, ultimately resulting in the continued deposition of excess extracellular matrix and 
collagen1. The notion of a crucial involvement of the immune system in the pathogenesis of lung fibrosis is chal-
lenged by the observation that ILD is in clinical practice not amenable to immunosuppression and that many 
patients have remarkably little cellular inflammation in affected lungs2,3.
Reactive oxygen species (ROS) in contrast may play an important role in the pathogenesis of idiopathic and 
CTD-related ILD. ROS are present at great abundance early in the disease evolution and are constitutively pro-
duced by pulmonary fibroblasts in ILD-patients4,5. The mechanism that initiates the generation of hydrogen per-
oxide and superoxide in CTD resides within the fibroblasts and is independent of cytokines6. Oxidant stress also 
enhances fibroblast proliferation and collagen formation6, possibly by activating latent TGFβ1, a process that 
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again promotes ROS formation7–9. This TGFβ1-cycle is responsible for the expression of genes associated with the 
epithelial mesenchymal transition i.e. the transformation of pulmonary epithelial cells to fibroblasts and myofi-
broblasts8,10,11. Interestingly, the precise source of ROS in human ILD is unknown.
Mitochondria may play an important role in the pathogenesis of ILD as firstly, they are the main source of 
ROS producers within cells and secondly are in turn themselves prone to an oxidative injury of their membranes, 
proteins and DNA, e.g. mitochondrial DNA (mtDNA). The mitochondrial genome is particularly predisposed 
to oxidative damage due to its proximity to the mitochondrial respiratory chain, its lack of protective histones 
and limited DNA repair mechanism12. Unopposed mtDNA mutagenesis by endogenous ROS may interfere with 
the correct synthesis of mitochondrial RNA templates for the mitochondrial respiratory chain protein subunits. 
The resulting respiratory chain dysfunction could then promote ROS formation, with ROS then either attacking 
the respiratory chain itself, or in turn damaging mtDNA12. ROS may therefore close a vicious circle consisting of 
entwined respiratory chain insults and mtDNA mutations. Mitochondrial ROS as potent drivers of TGFβ1 acti-
vation may then also contribute to the relentless progression of ILD6,8,13.
We have recently discovered enhanced mtDNA mutagenesis, ROS-formation and mtDNA-encoded respira-
tory chain dysfunction in bleomycin induced pulmonary fibrosis14. The aim of this investigation was therefore to 
study, if mitochondrial lesions are also associated with ROS-formation and the pathogenesis of ILD in humans.
Results
Patients and lung biopsies. This study is based on a total of 60 lung biopsies; 47 biopsies (24 from the 
upper lobe and 23 from the lower lobe) were from 30 adult ILD-patients. From 17 patients (Eleven CTD and five 
idiopathic ILD-patients, one unknown) we had paired biopsies from two different lobes. In 13 patients (four CTD 
and five idiopathic ILD-patients) only one sample was available for analysis; two patients had a biopsy from the 
upper lobe, eleven patients from the lower lobe.
Thirteen biopsies were obtained from 13 controls; seven biopsies were from the upper lobes and six from the 
lower lobes.
Fifteen ILD-patients (50%) had a CTD (seven of which had SSc) and 14 patients (47%) had idiopathic ILD 
(Table 1). In one ILD-patient (3%) this information was unavailable. Of note, controls were significantly older and 
more frequently current smokers than ILD-patients.
Mitochondrial function and ROS-formation in all lung biopsies. We compared the 47 lung biopsies 
from the ILD-patients with the 13 biopsies from controls (Table 1), the median pulmonary MDA content was 
slightly elevated in biopsies from ILD-patients (p = 0.044).
The activity of the mitochondrial respiratory chain (COX/SDH-activity ratio) was depressed in ILD compared 
with control biopsies (p < 0.001). Furthermore, the COX/SDH-activity ratio was negatively correlated with the 
pulmonary MDA (r = −0.84, p < 0.001; Fig. 1a).
The COX2/COX4-ratio was depressed in the lung biopsies from ILD-patients (median 0.6) in comparison 
with biopsies from controls (median 2.2; p < 0.001; Table 1). The COX2/COX4-ratio was moderately correlated 
with respiratory chain function in terms of the COX/SDH-activity ratio (r = 0.39, p < 0.001; Fig. 1b) and nega-
tively correlated with the pulmonary MDA content (r = −0.33, p = 0.005; Fig. 1c).
On the genetic level, wild-type mtDNA copy numbers per cell were slightly elevated in ILD-patients but total 
mtDNA amounts did not differ statistically between patients and controls (p = 0.088; Table 1). The common 
Characteristics Controls All ILD* CTD-related ILD Idiopathic ILD
p-value (controls 
vs all ILD)
n patients 13 30 15 14
Female sex 62 47 67 29 0.37
Age, mean years (SD) 67.4 (13.7) 50.0 (11.2) 49.1 (10.7) 51.0 (12.6) <0.001
Smoking behaviour
Never 10 44 50 36
0.16Previous 70 48 50 46
Current 20 8 0 18
FVC, % of predicted 101 (90–105) 84 (67–88) 85 (69–89) 83 (64–85) <0.001
n biopsies 13 47 26 19
MDA, μmol/g lung tissue 91 (87–101) 101 (91–131) 105 (90–133) 101 (96–117) 0.044
COX/SDH-ratio 0.12 (0.11–0.18) 0.10 (0.04–0.13) 0.10 (0.04–0.13) 0.10 (0.04–0.12) <0.001
mtDNA, copies/pulmonary cell 315 (267–471) 419 (323–527) 367 (301–484) 434 (365–542) 0.088
COX2/COX4-ratio 2.18 (2.10–2.43) 0.64 (0.51–0.89) 0.62 (0.51–0.89) 0.72 (0.53–0.89) <0.001
common deletion, % of mtDNA molecules 0 (0–13) 17 (0–32) 21 (0–36) 15 (0–29) <0.001
Table 1. Demographics and clinical characteristics of the study population and the study results of their lung 
biopsies. Presented are either percent or median (interquartile range) if not otherwise specified. COX2/COX4, 
cytochrome c-oxidase subunit 2 protein normalized for cytochrome c-oxidase subunit 4 protein; COX/SDH-
ratio, cytochrome c-oxidase/ succinate dehydrogenase activity ratio; CTD, connective tissue disease; ILD, 
interstitial lung disease; MDA, malondialdehyde; mtDNA, mitochondrial DNA; FVC, forced vital capacity; 
SD, standard deviation. *In one patient it is unknown if the patient suffered from a CTD-related ILD or an 
idiopathic IDL.
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mtDNA deletion was present at low levels in some control lungs (median percentage of mtDNA deletions 0%, 
Table 1). ILD-patients in contrast harboured significantly higher levels of the common deletion (median per-
centage of mtDNA deletions 17%, p < 0.001 vs controls, see also Supplementary Fig. 1). In all lung biopsies, the 
amounts of mtDNA deletions were negatively correlated with the COX/SDH-activity ratio (r = −0.59, p < 0.001; 
Fig. 1d) and the COX2/COX4-ratio (r = −0.49, p < 0.001; Fig. 1e). Conversely, the amounts of mtDNA deletions 
correlated positively with the MDA-content (r = 0.69, p < 0.001; Fig. 1f).
In summary, these data indicate that fibrotic lungs acquired high levels of dysfunctional mtDNA molecules, in 
association with depressed synthesis of mtDNA-encoded respiratory chain subunits, respiratory chain dysfunc-
tion and enhanced ROS-formation.
Comparison of upper and lower lung biopsies. Among those 17 patients of whom we had simultaneous 
biopsies from upper and lower lobes, the median MDA content was 30% higher in the lower lobes (121.5 μmol 
MDA/g tissue, IQR 99.0–139.5) than in the upper lobes (93.4 μmol MDA/g tissue, IQR 68.6–103.5; Fig. 2a). The 
median COX activity, normalized for the activity of SDH (which is solely encoded by nDNA) was however 41% 
lower in the basal lobe biopsies compared to upper lobe biopsies (p < 0.001; Fig. 2b). The COX2/COX4-ratio was 
35% lower (median COX2/COX4-ratio 0.52, IQR 0.46–0.66) in the biopsies from lower lobes as compared to 
their upper lobe counterparts (0.91, IQR 0.60–1.06, p < 0.001; Fig. 2c). Whereas the amount of wild-type mtDNA 
copies did not differ between the two biopsy sites (median 434, IQR 301–542 copies for upper lobe biopsies and 
441, IQR 338–606 copies in lower lobe biopsy sites, p = 0.83), the median amounts of the common deletion were 
elevated by 53% in lower compared to upper lobes (p < 0.001; Fig. 2d).
Figure 1. Correlations between pulmonary levels of malondialdehyde (MDA) as a surrogate of ROS formation, 
low COX/SDH-activity ratios as a marker of impaired mtDNA-encoded respiratory chain function, low COX2/
COX4-ratios as a measure of impaired mtDNA encoded protein synthesis, and the common mtDNA deletion as 
a marker of mtDNA mutagenesis. Depicted are all lung biopsies.
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These results demonstrate that in each of the examined individuals, mitochondrial alterations and 
ROS-formation are enhanced in the lower lobe regions, in agreement with the typical apicobasal gradient of 
fibrosis in ILD.
other predictors of Ros-formation and mitochondrial lesions. There was no association of any 
of these mitochondrial parameters and gender within patient or controls. The patients’ age was not associated 
with pulmonary MDA-levels (β = 0.29, 95%CI −0.7 to 1.3, p = 0.58), the COX/SDH-ratio (β = −0.0005, 95%CI 
−0.002 to 0.001, p = 0.63) and mtDNA copy numbers (β = −0.054, 95%CI −2.6 to 2.5, p = 0.97) in all biopsies, 
when accounting for patient groups. There was however a positive association between the frequency of the com-
mon mtDNA deletion and age (β = 0.31, 95%CI −0.007 to 0.6, p = 0.055 per 1-year increase in age) as well as a 
negative correlation between the COX2/COX4-ratio and age (β = −0.009, 95%CI −0.017 to −0.001, p = 0.022 
per 1-year increase in age). Smoking status was not associated with any of the assessed parameters (Table 2).
When comparing biopsies from idiopathic ILD with those of CTD-associated ILD, there was no difference 
with respect to MDA-levels (p = 0.65), the COX/SDH-ratio (p = 0.93), the COX2/COX4-ratio (p = 0.61), mtDNA 
copy numbers (p = 0.22) and the prevalence of the common deletion (p = 0.42). Similarly, there were no differ-
ences in mitochondrial parameters between lungs from patients with SSc and those with other CTDs (data not 
shown).
Discussion
The aim of this study was to investigate the role of mitochondrial dysfunction in the pathogenesis of both, idi-
opathic and CTD-related ILD and the relentless progression of ILD over time. We demonstrate in human lung 
biopsies, that fibrosis is associated with ROS-formation, mitochondrial dysfunction and the development of 
large-scale deletions in mtDNA as identified in our previous study in the bleomycin model of lung fibrosis14. 
Figure 2. Comparison of lung biopsy sites (upper vs. lower lobes) for (a) ROS-formation, (b) mtDNA encoded 
respiratory chain function, (c) mtDNA-encoded protein, (d) mtDNA mutations in those 17 ILD-patients in 
whom simultaneous biopsies were performed. Lines connect measurements from the same patient. Boxes 
represent the 25th, 50th and 75th percentiles; whiskers define the lowest and highest data point within 1.5 times 
the interquartile range.
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The mitochondrial lesions are unexplained by smoking status and were more protuberant in the lower than in 
the upper lobes, in line with the typical apicobasal gradient of fibrotic manifestations. Our data indicate that the 
respiratory impairment is associated with a selective impairment of mitochondrial, but not nuclear encoded 
respiratory chain subunits.
An aberrant response to recurrent insults is an important pathophysiological mechanism in the development 
of ILD1,15. Substantial evidence suggests that ROS of pulmonary origin drive the fibrotic process4,5,7. In search of 
a possible role of mitochondria in ROS-generation, data from the bleomycin model of lung fibrosis suggest that 
mtDNA insults could perpetuate ROS-formation and mitochondrial lesions14. The important contribution of 
ROS to lung fibrosis is also demonstrated by the observation that the absence of ROS protects against bleomycin 
mediated lung fibrosis16.
In the current study, we demonstrate that substantial mitochondrial dysfunction is likely to represent a sig-
nificant source of ROS in human lung fibrosis. mtDNA and respiratory chain insults could self-perpetuate each 
other and promote the relentless progression and subsequent age-related acquisition of lung fibrosis. Whereas it 
has been demonstrated that ROS can activate TGFβ1, a profibrotic cytokine8,17,18, it is only poorly understood, if 
mitochondrial dysfunction may also promote fibrosis by other mechanisms18, i.e. by directly triggering apoptosis 
in pulmonary tissues7. Recent studies in an in vivo model of acute lung injury have demonstrated a diminished 
synthesis of alveolar adenosine triphosphate in conjunction with mitochondrial dysfunction and a protective 
effect of normal mitochondrial bioenergetics19. Lastly, oxidative mtDNA damage impairs cell viability and pro-
motes netosis which is associated with an extracellular release of mtDNA molecules as damage-associated molec-
ular pattern and predictor of death in lung fibrosis20,21.
We have to acknowledge, that our patient and control populations were not age matched leading to an older 
control group. Age in our study was however associated with a well-known higher prevalence of mtDNA dele-
tions and depressed mtDNA encoded respiratory chain function22. The older control group would be as a conse-
quence of age rather be expected to have more mitochondrial lesions than the ILD patient group. We, however, 
found the opposite. Therefore, due to the age disparity between our patient and control group, we may have 
rather underestimated than overestimated the role of mitochondrial dysfunction in ILD identified in our study. 
Smoking is also a known inducer of oxidative stress23. Disparities of smoking behaviour between control and 
ILD-patients, are however unlikely to explain the differences of malondialdehyde content or mitochondrial func-
tion observed between control and ILD-patients, as smoking was not associated with any parameter. Lastly, it 
should be mentioned that we were unable to retrieve information of the patients’ treatment prior to the acquisi-
tion of the biopsies. It is however unlikely that the subjects under study had significant amounts of radiotherapy 
or chemotherapy before the lung biopsy, as the diagnosis triggering such therapeutic interventions usually require 
biopsy confirmation.
Our results do not provide proof of a causal role of mitochondrial dysfunction in ILD and we have to acknowl-
edge that we do not know which of the various pulmonary cells accounts for our findings. We have previously 
identified an architectural distortion of mitochondria in several pulmonary cell types, including alveolar epithe-
lial cells in ultrastructural studies of the bleomycin model of lung fibrosis14. Others have demonstrated accumu-
lation of dysmorphic and dysfunctional mitochondria in alveolar epithelial cells, fibroblasts and macrophages of 
idiopathic ILD-patients24. Preclinical models have demonstrated that alveolar epithelial cells acquire oxidative 
mtDNA lesions and that alveolar epithelial cell dysfunction in response to such injury is fundamental in the devel-
opment of ILD13,25. Lastly, it was shown that an enhancement of mtDNA repair capability in lung endothelial cells 
is able to antagonize their ROS-mediated mtDNA damage, cytotoxicity, and propensity to undergo apoptosis20.
In summary, our data demonstrate a profound distortion of mitochondrial function in idiopathic and 
CTD-associated ILD that could account for a self-perpetuating release of endogenous ROS as an important con-
tributor of fibrosis. These findings support the development of pharmacologic strategies aimed at enhancing 
pulmonary mtDNA repair and mitochondrial bioenergetics.
Never smokers Previous smokers Current smokers p-value
Cases
MDA, μmol/g lung tissue 98 (89–125) 103 (94–131) 100 (97–102) 0.52
COX/SDH-ratio 0.12 (0.09–0.14) 0.07 (0.03–0.11) 0.11 (0.10–0.13) 0.17
mtDNA, copies/pulmonary cell 385 (325–484) 414 (365–487) 426 (365–487) 0.92
COX2/COX4-ratio 0.81 (0.57–1.01) 0.64 (0.51–0.83) 0.73 (0.47–0.99) 0.28
common deletion, % of mtDNA molecules 8.0 (0–31) 24.3 (0–32) 27.1 (22–32) 0.21
Controls
MDA, μmol/g lung tissue 115 91 (66–102) 89 (87–91) 0.29
COX/SDH-ratio 0.14 0.12 (0.11–0.19) 0.15 (0.12–0.18) 0.82
mtDNA, copies/pulmonary cell 262 342 (304–504) 327 (315–339) 0.47
COX2/COX4-ratio 2.10 2.20 (1.98–2.44) 1.98 (1.79–2.18) 0.45
common deletion, % of mtDNA molecules 12.7 0 (0–14) 0 (0–0) 0.41
Table 2. Comparison of lung parameters in all lung biopsies by smoking status separate for lung fibrosis 
patients and controls. Presented are medians and interquartile ranges. COX2/COX4, cytochrome c-oxidase 
subunit 2 protein normalized for cytochrome c-oxidase subunit 4 protein; COX/SDH-ratio, cytochrome 
c-oxidase/succinate dehydrogenase activity ratio; MDA, malondialdehyde; mtDNA, mitochondrial DNA.
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Methods
Patients and lung biopsies. Adult patients of the Royal Brompton Hospital, London, UK with either idi-
opathic or CTD-related ILD were included in the study. All showed a histological pattern of fibrotic non-specific 
interstitial pneumonia (Fig. 3), one with coexistent organising pneumonia in the lower lobe. Control samples 
were taken from background lung of resections for lung cancer without interstitial fibrosis. All samples were 
surgical lung biopsies.
All patients signed an informed consent for the research use of their samples, and the study was conducted in 
accordance with the 1975 Declaration of Helsinki, as revised in 2008.
Ros products in lung tissue. The generation of ROS is an unavoidable by product of mitochondrial 
electron-transport. We spectrophotometrically quantified malondialdehyde (MDA) as one of the products of 
ROS-mediated lipid peroxidation by probing for thiobarbituric acid reactive material26.
Activity of mitochondrial respiratory chain complexes. The enzymatic activity of cytochrome 
c-oxidase (COX, also known as respiratory chain complex IV) was assessed in lung extracts by spectrophotom-
etry, as described27. The COX subunits are encoded in part by nuclear DNA (nDNA) and in part by mtDNA. We 
similarly quantified the enzymatic activity of succinate dehydrogenase (SDH) as the respiratory chain complex II 
which is entirely encoded by nDNA27.
MtDNA-encoded respiratory chain protein. The subunit-2 of cytochrome c-oxidase (COX2) is encoded 
by mtDNA, while subunit-4 of cytochrome c-oxidase (COX4) is encoded by nDNA. A low COX2/COX4-ratio is 
therefore an indicator of an impaired synthesis of mtDNA-encoded respiratory protein. Both COX subunits were 
quantified in lung tissues by immunoblot densitometry (Quantum ST4v16.03, Vilber Lourmat, Marne-la-Vallee, 
France)28.
MtDNA-content. Genomic DNA was extracted from lung tissues with a DNA isolation kit (QIAamp, 
Qiagen, Germany). MtDNA copy numbers were quantified on a 384 well plate by quantitative PCR using the 
LightCycler® 480 Real-Time PCR System (Roche, Germany). 10 μl reactions contained 5 μl of SYBR Green I 
Master mix (Roche, Germany) 10 ng DNA template and 0.5 μM of primers (5′-ACCAATAGCCCTGGCCGTAC-
3′and 5′-GGTGGCGCTTC-CAATTAGGT-3′)29. All samples were run in triplicate. MtDNA copy numbers were 
normalized for nDNA copy numbers of glycerol aldehyde phosphate dehydrogenase. Absolute mtDNA and 
nDNA copy numbers were measured by employing a standard curve with serial dilutions of mtDNA and nDNA 
plasmids. The mtDNA copy number per pulmonary cell was calculated as the number of mtDNA copies per two 
nDNA copies.
Quantification of the common mtDNA-deletion. During mtDNA replication, sequence base pairs 
may be deleted by slipped mispairing between direct nucleotide sequence repeats30. In humans, a 4977 base-pair 
deletion is the most prevalent result of slipped mispairing and therefore termed “common” deletion. We probed 
for the common mtDNA deletion by amplifying 100 ng of pulmonary DNA in a PCR reaction with extradele-
tional primers (5′-TAA TTC CCC TAA AAA TCT TTG AAAT-3′ and 5′-AAC CTG TGA GGA AAG GTA TTC 
CTGC-3′)31. By means of a short extension cycle (30 seconds), the deleted molecule was preferentially amplified 
as a 324 base-pair product (Supplementary Fig. 1) and confirmed by sequencing (MWG Biotech, Germany) to 
represent the common mtDNA deletion. The deletion was quantified on agarose gels with a standard curve of 
PCR products from known ratios of deleted and wild type mtDNA molecules as described elsewhere31.
statistics. Categorical variables are presented as frequencies/percentages and continuous variables as means/
standard deviations (SD) or medians/interquartile ranges (IQR). T-tests or Wilcoxon–Mann–Whitney tests were 
Figure 3. Fibrotic non-specific interstitial pneumonia (NSIP). The biopsy shows diffuse homogenous 
interstitial fibrosis associated with a mild non-specific chronic inflammatory cell infiltrate. Neither fibroblastic 
foci nor honeycomb change is seen (haematoxylin and eosin stain, x40).
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applied for across group comparisons in unpaired, non-clustered data and Somers’ D was used when all biopsies 
were included accounting for the biopsy clustering on the patient level. Paired Wilcoxon-signed-rank tests were 
used to assess differences of the measures in the upper vs lower lung biopsies. Correlations between continuous 
measures are stated as Pearson’s correlation coefficient. Linear regression analysis was applied to adjust for possi-
ble confounders. All data analyses were performed with Stata/IC 13.1 (StataCorp, College Station, USA).
Prior abstract publication/presentation. This study has been presented at the 2017 American College 
of Rheumatology (ACR) congress held in San Diego and at the Annual Congress of the SGR-SSR and HPR 
Symposium as a poster and at the 2018 European League against Rheumatology (EULAR) congress held in 
Amsterdam as an oral presentation.
ethical approval. Utilisation of archival frozen samples was approved by the Royal Brompton & Harefield 
NHS Foundation Trust (ethics approval reference EKBB 353/11).
Data Availability
The datasets analysed during the current study are available from the corresponding author on reasonable re-
quest.
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